Shares of H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) fell 49.5% on Friday . The stock traded as low as $2.02 and last traded at $2.02. 400 shares traded hands during mid-day trading, an increase of 288% from the average session volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Stock Down 49.5%
The business has a 50 day moving average price of $2.02 and a 200 day moving average price of $2.02.
H-CYTE Company Profile
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
Featured Articles
- Five stocks we like better than H-CYTE
- Alphabet’s Most Overlooked Division Just Had a Big Week
- Cooking Up Profits: Cracker Barrel’s Turnaround
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
